Program
Octreotide
Also written as “Sandostatin LAR Depot”, “Octreotide LAR” and “Sandostatin LAR”.
Its studies are mostly in Acromegaly · Obesity · Diarrhea · Malignant Carcinoid Syndrome · Thymoma, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 210 open or running | phase 4since Dec 17, 2002 | Nov 2, 1999 | none ahead |
| Keenova Therapeutics | 40 open or running | phase 3since Sep 30, 2008 | Sep 30, 2008 | none ahead |
| Chiesi Farmaceutici | 30 open or running | phase 3since Aug 5, 2011 | Aug 5, 2011 | none ahead |
| Ambrilia Biopharma | 10 open or running | phase 3since Mar 21, 2008 | Mar 21, 2008 | none ahead |
| Dauntless Pharmaceuticals | 10 open or running | phase 1since Jan 17, 2017 | Jan 17, 2017 | none ahead |
Also a collaborator on its studies: quintiles-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 16 studies since Nov 2, 1999.
- Sep 6, 2006Phase 3 study in AcromegalyNovartis · NCT00372697 · 28 enrolled · Italy
- Sep 13, 2006Phase 4 study in AcromegalyNovartis · NCT00376064 · 20 enrolled · Germany
- Dec 21, 2007Phase 1 study in Irritable Bowel SyndromeNovartis · NCT00584298 · 50 enrolled · United States, Canada, Sweden and more
- Dec 21, 2007Phase 3 study in Colorectal NeoplasmsNovartis · NCT00582426 · 139 enrolled · Brazil
- Mar 21, 2008Ambrilia Biopharma's first study: phase 3 study in AcromegalyNew to Ambrilia BiopharmaAmbrilia Biopharma · NCT00642421 · 40 enrolled · United States, Belarus, Hungary and more
- May 15, 2008Phase 3 study in Carcinoid TumorNovartis · NCT00690430 · 186 enrolled · United States, Argentina, Austria and more
- Sep 30, 2008Keenova Therapeutics's first study: phase 3 study in AcromegalyNew to Keenova TherapeuticsKeenova Therapeutics · NCT00765323 · 169 enrolled · United States, Czech Republic, Germany and more
- Apr 20, 2009Phase 2 study in Serotonin SyndromeKeenova Therapeutics · NCT00884715 · 10 enrolled · United States
- May 26, 2009Phase 2 study in AcromegalyKeenova Therapeutics · NCT00913055 · 34 enrolled
- Feb 10, 2011Phase 3 study in AcromegalyKeenova Therapeutics · NCT01295060 · 12 enrolled · United States
- Aug 5, 2011Chiesi Farmaceutici's first study: phase 3 study in AcromegalyNew to Chiesi FarmaceuticiChiesi Farmaceutici · NCT01412424 · 155 enrolled · United States, Germany, Hungary and more
- Jan 28, 2016Phase 3 study in AcromegalyChiesi Farmaceutici · NCT02685709 · 146 enrolled · United States, Austria, France and more
- Jan 17, 2017Dauntless Pharmaceuticals's first study: phase 1 study in Healthy Volunteer StudyNew to Dauntless PharmaceuticalsDauntless Pharmaceuticals · NCT03031535 · 32 enrolled · United States
- Aug 10, 2017Phase 3 study in AcromegalyChiesi Farmaceutici · NCT03252353 · 56 enrolled · United States, Australia, Bulgaria and more
TargetBeta
“Somatostatin receptor agonist”ChEMBL 37, by rule
Studies
All 30 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT03252353Acromegaly · United States, Australia, Bulgaria and more | 3 | UNKNOWN | Chiesi Farmaceutici | Jun 13, 2019 | 56 |
| NCT03031535Healthy Volunteer Study · United States | 1 | Completed | Dauntless Pharmaceuticals | Mar 2017 | 32 |
| NCT02685709Acromegaly · United States, Austria, France and more | 3 | Completed | Chiesi Farmaceutici | Oct 2020 | 146 |
| NCT01412424Acromegaly · United States, Germany, Hungary and more | 3 | Completed | Chiesi Farmaceutici | May 2014 | 155 |
| NCT01295060Acromegaly · United States | 3 | Terminated | Keenova Therapeutics | Apr 2012 | 12 |
| NCT00913055Acromegaly | 2 | Completed | Keenova Therapeutics | May 2007 | 34 |
| NCT00884715Serotonin Syndrome · United States | 2 | Terminated | Keenova Therapeutics | Nov 2011 | 10 |
| NCT00765323Acromegaly · United States, Czech Republic, Germany and more | 3 | Terminated | Keenova Therapeutics | Feb 2011 | 169 |
| NCT00690430Carcinoid Tumor · United States, Argentina, Austria and more | 3 | Completed | Novartis | Apr 2012 | 186 |
| NCT00642421Acromegaly · United States, Belarus, Hungary and more | 3 | Terminated | Ambrilia Biopharma | Aug 2009 | 40 |
| NCT00584298Irritable Bowel Syndrome · United States, Canada, Sweden and more | 1 | Completed | Novartis | Apr 2009 | 50 |
| NCT00582426Colorectal Neoplasms · Brazil | 3 | Completed | Novartis | Sep 2010 | 139 |
| NCT00376064Acromegaly · Germany | 4 | Completed | Novartis | Jan 2010 | 20 |
| NCT00372697Acromegaly · Italy | 3 | Completed | Novartis | Oct 2007 | 28 |
| NCT00332969Thymoma · Germany | 2 | Completed | Novartis | Oct 2010 | 25 |
| NCT00332696Peritoneal Neoplasms · France | 2 | Completed | Novartis | Sep 2008 | 64 |
| NCT00241020Carcinoma, Hepatocellular | 3 | Completed | Novartis | Oct 2005 | 270 |
| NCT00242541Acromegaly · Mexico | 4 | Terminated | Novartis | Aug 2005 | 50 |
| NCT00225979Acromegaly | 3 | Completed | Novartis | Mar 2005 | 100 |
| NCT00171886Acromegaly · Spain | 4 | Completed | Novartis | May 2006 | 20 |
| NCT00171613Sexual Infantilism | 4 | Completed | Novartis | Oct 2005 | 32 |
| NCT00170742Disease · Switzerland | 3 | Terminated | Novartis | May 2006 | 17 |
| NCT00166725Prostatic Neoplasms · Italy | 2 | Completed | Novartis | 40 | |
| NCT00128232Acromegaly | 3 | Completed | Novartis | Aug 2004 | 100 |
| NCT00094146Obesity · United States | 2 | Completed | Novartis | 160 | |
| NCT00076362Obesity · United States | 4 | Completed | Novartis | Jul 2005 | 60 |
| NCT00050635Neoplasms · United States | 4 | Completed | Novartis | 150 | |
| NCT00006269Colorectal Neoplasms · United States | 3 | Terminated | Novartis | Dec 1999 | 89 |
| NCT00002253Diarrhea · United States | – | Completed | Novartis | ||
| NCT00002252Diarrhea · United States | – | Completed | Novartis |
How it is read
Names in the registry
- “Octreotide”, 9 entries
- “Sandostatin LAR Depot”, 3 entries
- “Octreotide LAR”, 3 entries
- “Sandostatin LAR”, 3 entries
- “Octreotide capsules”, 2 entries
Conditions, from the studies’ own filings
- Acromegaly, 17 studies
- Obesity, 2 studies
- Diarrhea, 2 studies
- Malignant Carcinoid Syndrome, 1 study
- Thymoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.